These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 18086799)

  • 1. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
    Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
    J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
    Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
    J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
    Nogová L; Reineke T; Josting A; Müller-Hermelink HK; Eich HT; Behringer K; Müller RP; Diehl V; Engert A
    Eur J Haematol Suppl; 2005 Jul; (66):106-10. PubMed ID: 16007877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.
    Klimm B; Franklin J; Stein H; Eichenauer DA; Haverkamp H; Diehl V; Fuchs M; Borchmann P; Engert A
    J Clin Oncol; 2011 Oct; 29(29):3914-20. PubMed ID: 21911729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
    Mauz-Körholz C; Gorde-Grosjean S; Hasenclever D; Shankar A; Dörffel W; Wallace WH; Schellong G; Robert A; Körholz D; Oberlin O; Hall GW; Landman-Parker J
    Cancer; 2007 Jul; 110(1):179-85. PubMed ID: 17526010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
    Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
    J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group.
    Engert A; Ballova V; Haverkamp H; Pfistner B; Josting A; Dühmke E; Müller-Hermelink K; Diehl V;
    J Clin Oncol; 2005 Aug; 23(22):5052-60. PubMed ID: 15955904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
    Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
    Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group.
    Eichenauer DA; Bredenfeld H; Haverkamp H; Müller H; Franklin J; Fuchs M; Borchmann P; Müller-Hermelink HK; Eich HT; Müller RP; Diehl V; Engert A
    J Clin Oncol; 2009 Dec; 27(36):6079-85. PubMed ID: 19901121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
    Chen RC; Chin MS; Ng AK; Feng Y; Neuberg D; Silver B; Pinkus GS; Stevenson MA; Mauch PM
    J Clin Oncol; 2010 Jan; 28(1):136-41. PubMed ID: 19933914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.
    Wirth A; Yuen K; Barton M; Roos D; Gogna K; Pratt G; Macleod C; Bydder S; Morgan G; Christie D
    Cancer; 2005 Sep; 104(6):1221-9. PubMed ID: 16094666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodular lymphocyte-predominant Hodgkin's lymphoma.
    Nogovà L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2006 Mar; 1(1):60-5. PubMed ID: 20425333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
    Klimm B; Reineke T; Haverkamp H; Behringer K; Eich HT; Josting A; Pfistner B; Diehl V; Engert A;
    J Clin Oncol; 2005 Nov; 23(31):8003-11. PubMed ID: 16204002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma.
    Bräuninger A; Wacker HH; Rajewsky K; Küppers R; Hansmann ML
    Cancer Res; 2003 Apr; 63(7):1644-51. PubMed ID: 12670918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology.
    Pellegrino B; Terrier-Lacombe MJ; Oberlin O; Leblanc T; Perel Y; Bertrand Y; Beard C; Edan C; Schmitt C; Plantaz D; Pacquement H; Vannier JP; Lambilliote C; Couillault G; Babin-Boilletot A; Thuret I; Demeocq F; Leverger G; Delsol G; Landman-Parker J;
    J Clin Oncol; 2003 Aug; 21(15):2948-52. PubMed ID: 12885814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
    Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
    Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.